Trial Profile

Effects of Dapagliflozin on Biomarkers, Symptoms and Functional Status in Patients With PRESERVED Ejection Fraction Heart Failure

Status: Completed

Phase of Trial: Phase IV

Latest Information Update: 31 Dec 2024

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

18 Nov 2024 Results examining the interaction between baseline orthostatic PP, treatment, and outcomes during 12 weeks of follow-up, presented at the American Heart Association Scientific Sessions 2024
13 Nov 2023 Results of Patient-level data were pooled from the DEFINE-HF and PRESERVED-HF presented, at the American Heart Association Scientific Sessions 2023
01 Jul 2023 Results of pooled analysis of DEFINE-HF & PRESERVED-HF assessing effect of dapagliflozin on the change in the Kansas City Cardiomyopathy Questionnaire (KCCQ) Clinical Summary Score (CSS) at 12 weeks was tested with ANCOVA adjusted for sex, baseline KCCQ, EF, atrial fibrillation, estimated glomerular filtration rate, and type 2 diabetes, published in the Circulation: Heart Failure.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com